Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ginkgo Bioworks Holdings ( (DNA) ) has provided an announcement.
On May 27, 2025, Ginkgo Bioworks Holdings reached a Stipulation and Agreement of Settlement to resolve stockholder derivative actions against certain individuals. The settlement, preliminarily approved by the court on August 21, 2025, includes a $4,125,000 insurance-funded payment, corporate governance reforms, and the dismissal of the actions. A final hearing is set for December 18, 2025.
The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.
Spark’s Take on DNA Stock
According to Spark, TipRanks’ AI Analyst, DNA is a Neutral.
The overall stock score of 55 reflects a mixed outlook for Ginkgo Bioworks Holdings. The most significant factor is the company’s financial performance, which shows strong gross margins but struggles with profitability and cash flow. The technical analysis indicates a positive trend, while the earnings call highlights cost reductions and strategic growth initiatives. However, the negative valuation metrics and potential risks in biosecurity revenue and leasing challenges temper the overall score.
To see Spark’s full report on DNA stock, click here.
More about Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings operates in the biotechnology industry, focusing on the development of custom organisms for a variety of applications across multiple sectors, including pharmaceuticals, agriculture, and industrial chemicals.
Average Trading Volume: 1,574,557
Technical Sentiment Signal: Sell
Current Market Cap: $720.5M
Learn more about DNA stock on TipRanks’ Stock Analysis page.